ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and HypoglycemiaIRVINE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) — ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a key international patent from the State of Israel Patent Office for its Diabetes Neuromodulation technology. Patent Number 277949, entitled, “Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic

This article was originally published here.